Superbugs Epidemic to Spur Teva Supplier Growth

Superbugs Epidemic to Spur Teva Supplier Growth

Akos Stiller/Bloomberg

Venus, which gets about 4 percent of its revenue from selling to Israel’s Teva, has obtained a patent for Sulbactomax in 40 countries and plans to start sales in 20 nations by 2014.